Combining 2′-fucosyllactose and galacto-oligosaccharides exerts anti-inflammatory effects and promotes gut health

Le résumé fourni par la source

This study investigated the potential of 2'-fucosyllactose (2'-FL) and galacto-oligosaccharides (GOS) combinations as a novel and cost-effective substitute for human milk oligosaccharides (HMO) in promoting gut health and reducing inflammation. In vitro studies using caco-2 cells showed that 2'-FL and GOS combinations (H1 = GOS:2'-FL ratio of 1.8:1; H2 = GOS:2'-FL ratio of 3.6:1) reduced LPS-induced inflammation by decreasing pro-inflammatory markers, whereas individual treatments had no significant effects. In a mouse model of dextran sulfate sodium (DSS)-induced colitis, combined 2'-FL and GOS supplementation alleviated symptoms, improved gut permeability, and enhanced intestinal structure, with the GH1 group (H1 combo with DSS) being the most effective. 2'-Fucosyllactose and GOS combinations also enhanced short-chain fatty acid production in infant fecal batch fermentation and mouse fecal analysis, with GH1 showing the most promising results. The GH1 supplementation altered gut microbiota in mice with DSS-induced colitis, promoting microbial diversity and a more balanced Firmicutes to Bacteroidota ratio. Infant formula products (IFP) containing 2'-FL and GOS combinations (IFP2 = 174 mg of GOS and 95 mg of 2'-FL per 14 g serving, 1.8:1 ratio; IFP3 = 174 mg of GOS and 48 mg of 2'-FL per 14 g serving, 3.6:1 ratio) demonstrated gastrointestinal protective and anti-inflammatory properties in a co-culture model of caco-2 and THP-1 cells. These findings suggest that 2'-FL and GOS combinations have potential applications in advanced infant formulas and supplements to promote gut health and reduce inflammation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.